Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Lennard, A., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S., Shustov, A., Hüttmann, A., Savage, K. J., Yuen, S., Iyer, S., Zinzani, P. L., Hua, Z., Little, M., Rao, S., Woolery, J., Manley, T., Trümper, L., & , (2019). brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, 393(10168), 229–240. http://access.bl.uk/ark:/81055/vdc_100076796556.0x000049